NCT00925821 - Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | Biotech Hunter

Enrollment

146

Participants

Timeline

Start Date

June 30, 2009

Conditions

Multiple Myeloma

Interventions

PROCEDURE

allogeneic stem cell transplant versus second autologous transplantation

Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²

DRUG

RAD

After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.

Trial Locations (12)

18057

Rostock University Hospital, Rostock

24105

Kiel University Hospital, Kiel

79106

Freiburg University Hospital, Freiburg im Breisgau

81377

Munich Grosshadern University Hospital, Munich

81675

University Hospital of Munich Technical University, Munich

89081

Ulm University Hospital, Ulm

90419

Klinikum Nuremberg, Nuremberg

91054

Erlangen University Hospital, Erlangen

93053

Regensburg University Hospital, Regensburg

Unknown

Charité University Hospital - Virchow Klinikum, Berlin

Jena University Hospital, Jena

01307

Dresden University Hospital, Dresden